Related Experiment Videos
Carbamazepine for cocaine dependence.
A R Lima1, M S Lima, B G Soares
1Centro de Medicina Baseada em Evidências, Universidade Federal de Pelotas, Av. Duque de Caxias, 250, Pelotas, RS, Brazil, 96100. mslima@nutecnet.com.br
The Cochrane Database of Systematic Reviews
|November 1, 2001
Summary
Carbamazepine (CBZ) does not show significant effectiveness in treating cocaine dependence, with no improvements in cocaine metabolite levels. While slightly reducing anxiety, it increased side effects, indicating a need for further research on more promising treatments.
Area of Science:
- Addiction Medicine
- Psychopharmacology
- Clinical Trials
Background:
- Cocaine dependence presents significant public health challenges, including medical, psychological, and social issues.
- Pharmacotherapy is a key component in treating cocaine dependence, but effective options remain limited.
- Carbamazepine (CBZ), an anticonvulsant, has been explored for cocaine dependence treatment, yet its efficacy is unproven.
Purpose of the Study:
- To evaluate the effectiveness of carbamazepine (CBZ) in treating individuals with cocaine dependence.
- To synthesize evidence from randomized controlled trials (RCTs) comparing CBZ to placebo for cocaine dependence.
Main Methods:
- A systematic review of randomized controlled trials (RCTs) was conducted.
- Searches included major databases (Cochrane, MEDLINE, EMBASE, PsycLIT) and other sources up to October 1997.
- Inclusion criteria focused on RCTs of carbamazepine versus placebo for cocaine dependence, including those with co-occurring opiate dependence.
Main Results:
- Five studies with 455 participants were analyzed; no significant differences in urine cocaine metabolite levels were observed.
- Carbamazepine showed a non-significant trend towards reducing anxiety scores but was associated with a higher incidence of side effects.
- Dropout rates were high in both groups, with slightly fewer dropouts in the carbamazepine group, but this was not statistically significant when excluding side-effect-related dropouts.
Conclusions:
- Current evidence does not support the clinical use of carbamazepine for treating cocaine dependence.
- Larger, well-designed randomized trials are needed for medications demonstrating more promising efficacy.
- Further research should focus on treatments with stronger evidence of effectiveness for cocaine dependence.